Latest Research And Development News

Nuix Limited reported a slight revenue increase to $221.5 million for FY25 but swung to a net loss of $9.2 million, weighed down by rising legal fees and restructuring costs. The company’s AI-driven Nuix Neo platform showed strong contract growth, while cash EBITDA improved significantly.

IMDEX Limited posted a modest 3% revenue decline in FY25 but delivered a robust 15% rise in EBITDA and a striking 70% jump in net profit, driven by strong growth in digital and SaaS platforms. The company’s strategic acquisitions and sustained R&D investment position it well for future expansion.

Cogstate Limited has reported a landmark FY25 with revenue up 22% and net profit before tax nearly doubling, driven by a surge in clinical trials contracts and strategic innovation. The company also declared its maiden fully franked dividend and outlined ambitious growth plans including AI product launches and an expanding Medidata partnership.

BrainChip Holdings reports a significant revenue surge and reduced losses in H1 2025, underpinned by new contracts, strategic collaborations, and an expanded funding agreement.

PWR Holdings Limited posted a 6.7% revenue decline and a 60.6% drop in net profit for FY2025, impacted by contract completions and factory relocation. Despite short-term setbacks, the company is investing heavily in new facilities, aerospace growth, and sustainability initiatives.

Objective Corporation Limited reported a robust FY2025 with 15% growth in annualised recurring revenue, driven by strong SaaS adoption and strategic AI integration across its GovTech portfolio.

Objective Corporation Limited reported a solid 5% revenue increase to $123.5 million and a 13% rise in net profit after tax to $35.44 million for FY2025, alongside a strategic acquisition that broadens its e-planning software portfolio.

Codan Limited reported a robust FY25 with 22% revenue growth to $674.2 million and a 27% jump in net profit, driven by organic expansion and strategic acquisitions. The company’s communications and metal detection segments both posted solid gains, setting a confident tone for FY26.

Medical Developments International Ltd reported an 18% increase in revenue to $39.1 million for FY25, returning to profitability with a net profit after tax of $0.1 million. The company advanced its Penthrox market expansion through regulatory approvals and new partnerships.

Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial growth and strategic investments, while advancing key clinical trials and maintaining full-year guidance.

Telix Pharmaceuticals reported a robust 63% increase in revenue to $390.4 million for the first half of 2025, driven by strong Illuccix sales and the acquisition of RLS Radiopharmacies. Despite this growth, the company recorded a net loss of $2.3 million, reflecting increased investments and finance costs.

Li-S Energy Limited reported a $6.41 million net loss for FY25 while making significant strides in commercialising its lithium-sulfur battery technology, including commissioning new production facilities and securing key strategic partnerships.